Greenwich Lifesciences Inc
Veridion Score
BETALOW CONF · 5/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is GLSI moving today?
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
GLSI overview
Related filings and maps
Congress activity in GLSI
No receipt-qualified Congressional disclosure is present for GLSI in the cached public ledger.
GLSI contract awards, year to date.
Public federal awards linked to this ticker.
GLSI lobbying filings, year to date.
Registered lobbying filings matched to Greenwich Lifesciences Inc.